{"id":201397,"name":"AMGEN, INC.","slug":"amgen-inc","state":"DC","country":"United States of America","description":"biopharmaceutical company","totalSpending":1680000,"filings":29,"yearlySpending":[{"year":2019,"income":240000},{"year":2020,"income":240000},{"year":2021,"income":240000},{"year":2022,"income":240000},{"year":2023,"income":240000},{"year":2024,"income":240000},{"year":2025,"income":240000}],"issues":["HCR","MMM","IMM"],"firms":["MILLER STRATEGIES, LLC"],"lobbyists":["JEFFREY MILLER","ASHLEY GUNN","KELSEY GORMAN"],"govEntities":["Executive Office of the President (EOP)","HOUSE OF REPRESENTATIVES","Health & Human Services, Dept of (HHS)","SENATE","Centers For Medicare and Medicaid Services (CMS)"],"sampleDescriptions":["Healthcare policy issues as they relate to the pharmaceutical industry including prescription drug value issues, FDA and biosimilars.","Healthcare policy issues as they relate to the pharmaceutical industry including prescription drug value issues, FDA and biosimilars.","Monitoring issues related to drug pricing and Medicare Part D.","Healthcare policy issues as they relate to the pharmaceutical industry including drug pricing and biosimilars.","Issues related to drug pricing, biosimilars, Medicare Part D and Medicare Part B."],"years":[2019,2020,2021,2022,2023,2024,2025]}